MCID: HMN014
MIFTS: 62

Human Immunodeficiency Virus Infectious Disease

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 12 15
Hiv Infection 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:526
ICD9CM 36 042 042-042.99
MeSH 45 D015658
NCIt 51 C3108
SNOMED-CT 69 86406008
ICD10 34 B20 B20-B20
UMLS 74 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary : Human Immunodeficiency Virus Infectious Disease, also known as hiv infection, is related to aids dementia complex and acquired immunodeficiency syndrome. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ribavirin and Pentoxifylline have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are hematopoietic system and digestive/alimentary

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1059)
# Related Disease Score Top Affiliating Genes
1 aids dementia complex 32.8 B2M CXCR4 ITIH4 TNF
2 acquired immunodeficiency syndrome 32.0 B2M CCR5 CD38 CD4 IL2 IL6
3 human immunodeficiency virus type 1 32.0 APOBEC3G B2M CCL4 CCL5 CCR5 CD28
4 meningitis 31.4 CCL4 IL6 TNF
5 pulmonary tuberculosis 31.2 CCL4 IL2 TNF
6 toxoplasmosis 31.1 CCR5 IL6 TNF
7 encephalitis 30.9 CCL5 CCR5 ERVW-1 ITIH4
8 cytomegalovirus infection 30.8 B2M CCL5 IL6 TNF
9 lymphoma, non-hodgkin, familial 30.8 B2M CD38 CXCR4 IL2
10 meningoencephalitis 30.8 B2M CCL5 IL6
11 yellow fever 30.8 CCL5 CCR5 IL6
12 bone disease 30.6 B2M CCL4 IL6 TNF
13 peritonitis 30.5 B2M IL6 TNF
14 exanthem 30.4 IL2 IL6 TNF
15 myocardial infarction 30.4 CCL5 CCR5 CXCR4 IL6 S100B TNF
16 brucellosis 30.4 IL2 IL6 TNF
17 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.4 APOBEC3G CCL4 CCR5 CD4 CXCR4 ERVW-1
18 bronchiolitis 30.4 CCL5 IL6 TNF
19 hematopoietic stem cell transplantation 30.3 IL2 IL6 TNF
20 syphilitic meningitis 30.3 ENPEP ITIH4
21 pulmonary sarcoidosis 30.3 CCL5 CCR5 IL2 TNF
22 bone inflammation disease 30.3 IL2 IL6 TNF
23 chagas disease 30.3 CCR5 IL2 IL6 TNF
24 paracoccidioidomycosis 30.2 IL2 IL6 TNF
25 pulmonary disease, chronic obstructive 30.1 CCL5 IL6 SERPINA3 TNF
26 bacterial meningitis 30.1 IL6 S100B TNF
27 oral tuberculosis 30.1 IL2 TNF
28 myeloma, multiple 30.1 B2M CD38 CXCR4 IL2 IL6 TNF
29 sleep apnea 30.1 IL6 S100B TNF
30 plasmacytoma 30.1 B2M CD38 IL2 IL6
31 monoclonal gammopathy of uncertain significance 30.1 B2M CD38 IL6 TNF
32 behcet syndrome 30.1 CCR5 IL2 IL6 TNF
33 systemic lupus erythematosus 30.0 CCL5 CCR5 CD28 IL2 IL6 TNF
34 malaria 30.0 CCL4 CCL5 IL2 IL6 TNF
35 extramedullary plasmacytoma 30.0 B2M IL2 IL6
36 aphthous stomatitis 30.0 IL2 IL6 TNF
37 prostatitis 30.0 IL2 IL6 TNF
38 chikungunya 29.9 CCL5 IL6 TNF
39 multiple sclerosis 29.9 CCL5 CCR5 ERVW-1 IL2 IL6 TNF
40 toxic shock syndrome 29.9 IL2 IL6 TNF
41 rheumatoid arthritis 29.9 CCL5 CD28 IL2 IL6 TNF
42 common variable immunodeficiency 29.9 CD28 CD38 IL2 IL6 TNF
43 filariasis 29.9 CCL5 IL2 IL6 TNF
44 trypanosomiasis 29.8 CCL5 IL2 IL6 TNF
45 intestinal disease 29.8 IL2 IL6 TNF
46 leukemia, chronic lymphocytic 29.7 B2M CD38 CXCR4 IL2
47 interstitial lung disease 29.7 CCL5 IL6 TNF
48 susceptibility/resistance to hiv infection 12.3
49 immunodeficiency 13 11.4
50 anus cancer 11.4

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 B2M CCL5 CCR5 CCR6 CD28 CD38
2 digestive/alimentary MP:0005381 9.86 B2M CCR5 CD28 CD4 CXCR4 IL2
3 immune system MP:0005387 9.73 B2M CCL5 CCR5 CCR6 CD28 CD38
4 neoplasm MP:0002006 9.23 B2M CCR5 CD28 CXCR4 IL2 IL6

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
2
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
3
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1004316-88-4
4
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 206361-99-1, 635728-49-3 213039
5
Rilpivirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 500287-72-9
6
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136470-78-5 441300 65140
7
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 134678-17-4 60825
8
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147127-20-6 464205
9
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 143491-57-0 60877
10
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 644073 40400
11
Lopinavir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 192725-17-0 92727
12
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 155213-67-5 392622
13
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3056-17-5 18283
14
Rifabutin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 72559-06-9 46783538 6323490
15
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 738-70-5 5578
16
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 723-46-6 5329
17
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154598-52-4 64139
18
Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1051375-16-6 54726191
19
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
20
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
21
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 564-25-0 54671203
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
23
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5381226 5458213
24
Lumefantrine Approved Phase 4,Phase 3,Phase 1,Not Applicable 82186-77-4 6437380
25
Artemether Approved Phase 4,Phase 3,Phase 1,Not Applicable 71963-77-4 68911 119380
26
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 129618-40-2 4463
27
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
28
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 30516-87-1 35370
29
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159989-64-7 64143
30
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69655-05-6 50599
31
Amprenavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161814-49-9 65016
32
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 376348-65-1 3002977
33
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
34
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
35
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
37
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
39
Ezetimibe Approved Phase 4,Phase 1,Not Applicable 163222-33-1 150311
40
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81093-37-0 54687
41
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 49562-28-9 3339
42
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
43
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-96-4 1046
44
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 74-55-5 14052 3279
45
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 5280965 14956
46
Alendronate Approved Phase 4,Phase 3,Phase 2 66376-36-1, 121268-17-5 2088
47
Calcium Carbonate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 471-34-1
48
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
49
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
50
Desogestrel Approved Phase 4,Phase 2,Not Applicable 54024-22-5 40973

Interventional clinical trials:

(show top 50) (show all 9540)
# Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
3 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
4 Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
5 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
6 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
7 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
8 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
9 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
10 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
11 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
12 RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
13 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
14 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
15 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
16 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
17 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
18 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
19 Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM Unknown status NCT02844634 Phase 4 Doxycycline 100mg PO daily x 12 months;Tenofovir/emtricitabine 200/300mg PO daily;Doxycycline 100mg PO daily x 6 months
20 Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
21 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
22 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
23 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
24 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
25 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4 Isoniazid
26 Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients Unknown status NCT03041051 Phase 4
27 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
28 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
29 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
30 PrEP Demonstration Project (PRELUDE Study) Unknown status NCT02206555 Phase 4 emtricitabine/tenofovir disoproxil fumarate
31 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
32 Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection Unknown status NCT02691065 Phase 4 Integrase Inhibitor
33 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
34 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
35 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
36 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
37 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
38 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4 Rosuvastatin
39 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
40 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
41 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4 raltegravir
42 Atazanavir/r + Lamivudine Dual Therapy Unknown status NCT01599364 Phase 4 Atazanavir, ritonavir, lamivudine
43 Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens Unknown status NCT00940771 Phase 4 Boosted Atazanavir
44 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
45 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
46 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
47 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
48 Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
49 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
50 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Unknown status NCT01031069 Phase 4

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

MalaCards organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

42
Testes, T Cells, Liver, Bone, Kidney, Lung, Brain

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 4824)
# Title Authors Year
1
First Case of Acquired Hemophilia B in a Patient with HIV Infection: Case Report and Literature Review. ( 31106079 )
2019
2
Impact of reproductive aging on the vaginal microbiome and soluble immune mediators in women living with and at-risk for HIV infection. ( 31026271 )
2019
3
T-cell immunity against cytomegalovirus in HIV infection and aging: relationships with inflammation, immune activation, and frailty. ( 30900090 )
2019
4
Various associations of aging and long-term HIV infection with different neurocognitive functions: detailed analysis of a Japanese nationwide multicenter study. ( 30859496 )
2019
5
Impact of aging and HIV infection on serologic response to seasonal influenza vaccination: Erratum. ( 30829752 )
2019
6
HIV infection across aging: Synergistic effects on intrinsic functional connectivity of the brain. ( 29906495 )
2019
7
Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. ( 30788159 )
2019
8
Psychosis of dual origin in HIV infection: Viral escape syndrome and autoimmune encephalitis. ( 31041138 )
2019
9
Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. ( 30888569 )
2019
10
Hospital Onset Varicella Central Nervous System Vasculitis in a Patient with HIV Infection. ( 30715900 )
2019
11
18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection. ( 31089075 )
2019
12
Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. ( 30907775 )
2019
13
HIV infection is not associated with the initiation of curative treatment in women with cervical cancer in Botswana. ( 30801696 )
2019
14
Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection. ( 31046767 )
2019
15
Relationship between depression and risk behaviors in a US Military population with HIV infection. ( 30917666 )
2019
16
Diarrhea caused by Shigella flexneri in patients with primary HIV infection. ( 31046618 )
2019
17
Cognitive and Motor Impairment Severity Related to Signs of Subclinical Wernicke's Encephalopathy in HIV Infection. ( 30958387 )
2019
18
Association of HIV Infection with Epilepsy and Other Comorbid Conditions. ( 31054031 )
2019
19
Refractory ascites as a presenting feature of extramedullary plasmacytoma in an end-stage renal disease patient with HIV infection. ( 30838169 )
2019
20
A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. ( 31045941 )
2019
21
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease. ( 30905208 )
2019
22
Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. ( 30926447 )
2019
23
Notes from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018. ( 30973852 )
2019
24
Occult hepatitis B and HIV infection. ( 30969194 )
2019
25
HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. ( 30845068 )
2019
26
The impact of HIV infection and MSM status on hepatitis A infection: the experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period. ( 30801838 )
2019
27
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. ( 30653226 )
2019
28
Hepatocellular carcinoma: Clinical-pathological features and HIV infection in Mozambican patients<sup/>. ( 30903933 )
2019
29
Progressive disseminated histoplasmosis in Latin America and the Caribbean in people receiving highly active antiretroviral therapy for HIV infection: A systematic review. ( 30668766 )
2019
30
IgG4-related disease in a patient with HIV infection. ( 30988103 )
2019
31
Intestinal Spirochetosis Resembles Inflammatory Bowel Disease in a Patient With HIV Infection. ( 30098947 )
2019
32
Appendiceal Inflammatory Myofibroblastic Tumor and HIV Infection, An Association Not To Be Missed. ( 30918617 )
2019
33
Letter in Reply: Appendiceal Inflammatory Myofibroblastic Tumor and HIV Infection, An Association Not To Be Missed. ( 30918618 )
2019
34
Case 11-2019: A 49-Year-Old Man with HIV Infection and Chronic Kidney Disease. ( 30970193 )
2019
35
Short-term outcomes for lung cancer resection surgery in HIV infection. ( 30889013 )
2019
36
HIV infection compounds the lymphopenia associated with cerebral malaria in Malawian children. ( 30588141 )
2019
37
Tuberculous meningoencephalitis in patient with HIV-infection. ( 31076760 )
2019
38
A Rare Case of Neurosyphilis with Ocular Involvement in a Patient with HIV Infection and New Onset Syphilis. ( 31011497 )
2019
39
Is treated HIV infection associated with knee cartilage degeneration and structural changes? A longitudinal study using data from the osteoarthritis initiative. ( 31054571 )
2019
40
Acute purulent pericarditis due co-infection with Staphylococcus aureus and Mycobacterium tuberculosis as first manifestation of HIV infection. ( 30800325 )
2019
41
Bilateral non-tender parotidomegaly: a clue for underlying HIV infection and lymphocytic interstitial pneumonia. ( 31040143 )
2019
42
HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia. ( 31091258 )
2019
43
Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report. ( 31105941 )
2019
44
Psoriasis in HIV infection: an update. ( 30813860 )
2019
45
Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. ( 30891751 )
2019
46
Erythrodermic Psoriasis and HIV Infection. ( 30601728 )
2019
47
Cognitive Impairment in Zambians With HIV Infection and Pulmonary Tuberculosis. ( 30531294 )
2019
48
Factors associated with risk of HIV-infection among pregnant women in Cameroon: Evidence from the 2016 national sentinel surveillance survey of HIV and syphilis. ( 30978189 )
2019
49
HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. ( 31074723 )
2019
50
Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer's disease? ( 30868421 )
2019

Variations for Human Immunodeficiency Virus Infectious Disease

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Pathways for Human Immunodeficiency Virus Infectious Disease

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 B2M CCL4 CCL5 CCR5 CCR6 CD28
2
Show member pathways
13.85 CCL4 CCL4L1 CCL5 CCR5 CCR6 CD28
3
Show member pathways
13.63 CCL4 CCL4L1 CCL5 CCR5 CCR6 CD28
4
Show member pathways
13.34 B2M CCL4 CCL5 CCR5 CD4 IL2
5
Show member pathways
13.26 CCL4 CCL4L1 CCL5 CCR5 CCR6 CD28
6
Show member pathways
13.08 CCL4 CCL4L1 CCL5 IL2 IL6 TNF
7
Show member pathways
12.94 CCL5 CCR5 CD4 CXCR4 IL6 TNF
8
Show member pathways
12.87 B2M CD28 CD4 CXCR4 IL2 IL6
9
Show member pathways
12.86 CCL4 CCL4L1 CCL5 CCR5 CCR6 CD4
10
Show member pathways
12.77 CCL4 CCL4L1 CCL5 IL6 S100B TNF
11
Show member pathways
12.76 CCL4 CCL4L1 CCL5 CCR5 CCR6 CD28
12
Show member pathways
12.59 CD28 CD4 IL2 IL6 TNF
13
Show member pathways
12.54 CCR5 CD28 CD4 IL2 IL6 TNF
14 12.52 B2M CCL5 CD28 CD38 CXCR4 IL2
15
Show member pathways
12.33 CCL5 IL2 IL6 SERPINA3 TNF
16
Show member pathways
12.23 CCL4 CCL4L1 CCL5 CCR5 CCR6 CXCR4
17
Show member pathways
12.16 APOBEC3G B2M CCL4 CCL4L1 CCL5 CCR5
18
Show member pathways
12.07 CCL4 CCL5 CD4 IL2 IL6
19
Show member pathways
12.05 CD28 CD4 IL2 IL6 TNF
20
Show member pathways
11.97 CCL4 CCL5 CCR5 CCR6 CXCR4
21 11.9 CD38 CD4 IL6 TNF
22 11.88 CCR5 CXCR4 IL2 IL6
23 11.87 CCL5 CD28 IL6 TNF
24 11.86 CCL4 CCL4L1 TNF
25
Show member pathways
11.81 B2M CD28 CD4
26 11.8 CCR6 CD4 IL2 TNF
27 11.8 CD28 CD38 CD4 IL2 IL6 TNF
28 11.79 CCL4 CCL4L1 IL6
29 11.7 CD38 CD4 IL2 IL6 TNF
30
Show member pathways
11.69 B2M CCL4 CCL4L1 CCR5 CD4 IL2
31 11.67 CCL4 CCL5 IL6 TNF
32
Show member pathways
11.65 IL2 IL6 TNF
33 11.65 CCL4 CCL5 IL2 IL6 TNF
34
Show member pathways
11.63 B2M IL2 TNF
35 11.57 CD38 CD4 CXCR4
36 11.55 IL2 IL6 TNF
37 11.49 CD28 CD4 IL2
38 11.41 CCL4 CCL5 CCR5 IL6 TNF
39 11.26 CD4 IL2 IL6 TNF
40 11.25 CD28 CD4 IL2
41 11.18 CCL4 CCL4L1 CCL5 IL2 IL6 TNF
42 11.02 CCL4 CCL4L1 CCL5 IL2 IL6 TNF

GO Terms for Human Immunodeficiency Virus Infectious Disease

Cellular components related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 B2M CCL4 CCL5 IL2 IL6 ITIH4
2 extracellular space GO:0005615 9.81 B2M CCL4 CCL4L1 CCL5 IL2 IL6
3 cell surface GO:0009986 9.56 B2M CCR5 CCR6 CD28 CD38 CD4
4 external side of plasma membrane GO:0009897 9.23 B2M CCR5 CCR6 CD28 CD4 CXCR4

Biological processes related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.97 CCL5 CCR5 IL2 TNF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 CCL4 CCL4L1 CCL5 CD4 TNF
3 regulation of signaling receptor activity GO:0010469 9.96 CCL4 CCL5 IL2 IL6 TNF
4 cell-cell signaling GO:0007267 9.95 CCL4 CCL5 CCR5 ENPEP IL2
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.91 CD4 S100B TNF TRIM5
6 chemotaxis GO:0006935 9.91 CCL4 CCL5 CCR5 CCR6 CXCR4
7 response to virus GO:0009615 9.88 CCL4 CCL5 CXCR4 TNF
8 positive regulation of cytosolic calcium ion concentration GO:0007204 9.88 CCR5 CCR6 CD38 CXCR4 IL2
9 cellular response to interferon-gamma GO:0071346 9.87 CCL4 CCL4L1 CCL5
10 calcium-mediated signaling GO:0019722 9.87 CCR5 CCR6 CXCR4
11 cytokine-mediated signaling pathway GO:0019221 9.87 CCL4 CCL5 CCR5 CD4 IL2 IL6
12 neutrophil chemotaxis GO:0030593 9.86 CCL4 CCL4L1 CCL5
13 cellular response to interleukin-1 GO:0071347 9.85 CCL4 CCL4L1 CCL5
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.85 CCL5 CD28 TNF
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 CCL5 IL2 IL6
16 response to glucocorticoid GO:0051384 9.83 IL6 S100B TNF
17 cell chemotaxis GO:0060326 9.83 CCL5 CCR5 CCR6 CXCR4
18 apoptotic signaling pathway GO:0097190 9.82 CD28 CD38 TNF
19 response to cytokine GO:0034097 9.81 CCL5 CD38 ITIH4
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 CCL5 IL6 TNF
21 humoral immune response GO:0006959 9.8 CCR6 CD28 IL6 TNF
22 negative regulation of viral genome replication GO:0045071 9.78 APOBEC3G CCL5 TNF
23 acute-phase response GO:0006953 9.77 IL6 ITIH4 SERPINA3
24 lymphocyte chemotaxis GO:0048247 9.77 CCL4 CCL4L1 CCL5
25 chemokine-mediated signaling pathway GO:0070098 9.77 CCL4 CCL4L1 CCL5 CCR5 CCR6
26 monocyte chemotaxis GO:0002548 9.76 CCL4 CCL4L1 CCL5 IL6
27 regulation of defense response to virus by virus GO:0050690 9.75 B2M CD28 CD4
28 eosinophil chemotaxis GO:0048245 9.71 CCL4 CCL4L1 CCL5
29 negative regulation of bone resorption GO:0045779 9.7 CD38 IL6
30 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.69 CD28 CD4
31 negative regulation by host of viral transcription GO:0043922 9.69 CCL4 CCL5
32 positive regulation of immunoglobulin secretion GO:0051024 9.68 IL2 IL6
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 CD28 IL2
34 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
35 regulation of T cell activation GO:0050863 9.66 CCL5 CD4
36 positive regulation of T cell proliferation GO:0042102 9.65 CCL5 CD28 CD4 IL2 IL6
37 negative regulation of macrophage apoptotic process GO:2000110 9.63 CCL5 CCR5
38 positive regulation of natural killer cell chemotaxis GO:2000503 9.62 CCL4 CCL5
39 positive regulation of neuroinflammatory response GO:0150078 9.62 IL6 TNF
40 fusion of virus membrane with host plasma membrane GO:0019064 9.61 CCR5 CD4 CXCR4
41 entry into host cell GO:0030260 9.58 CCR5 CD4 CXCR4
42 inflammatory response GO:0006954 9.56 CCL4 CCL4L1 CCL5 CCR5 CXCR4 IL6
43 dendritic cell chemotaxis GO:0002407 9.46 CCL5 CCR5 CCR6 CXCR4
44 immune response GO:0006955 9.36 B2M CCL4 CCL5 CCR5 CCR6 CD28
45 G protein-coupled receptor signaling pathway GO:0007186 10.19 CCL4 CCL4L1 CCL5 CCR5 CCR6 CXCR4
46 viral process GO:0016032 10.05 APOBEC3G CCR5 CD4 CXCR4 TRIM5

Molecular functions related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.7 CCR5 CD4 CXCR4
2 chemokine activity GO:0008009 9.65 CCL4 CCL4L1 CCL5
3 CCR chemokine receptor binding GO:0048020 9.61 CCL4 CCL4L1 CCL5
4 chemokine binding GO:0019956 9.58 CCR5 CCR6 CXCR4
5 cytokine activity GO:0005125 9.55 CCL4 CCL5 IL2 IL6 TNF
6 C-C chemokine binding GO:0019957 9.54 CCR5 CCR6 CXCR4
7 C-C chemokine receptor activity GO:0016493 9.5 CCR5 CCR6 CXCR4
8 CCR5 chemokine receptor binding GO:0031730 9.49 CCL4 CCL5
9 CCR1 chemokine receptor binding GO:0031726 9.46 CCL4 CCL5
10 chemokine receptor activity GO:0004950 9.43 CCR5 CCR6 CXCR4
11 identical protein binding GO:0042802 9.32 APOBEC3G B2M CCL4 CCL5 CD28 CD38
12 coreceptor activity GO:0015026 9.26 CCR5 CD28 CD4 CXCR4
13 protein binding GO:0005515 10.44 APOBEC3G B2M CCL4 CCL4L1 CCL5 CCR5

Sources for Human Immunodeficiency Virus Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....